Pharmaceutical News

RSS

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Van Andel Research Institute researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

19 Feb 2010

Valensa International enters into license agreement with Biova for BiovaFlex ingredient

Valensa International (Eustis, FL USA) announced today that it has entered into a license agreement with Biova, LLC (Johnston, Iowa USA) that will allow Valensa to include the patented BiovaFlex(TM) water-soluble egg shell membrane ingredient in a proprietary new series of formulated joint health products.

19 Feb 2010

Report examines how medical technology changes state of health care

Federal researchers Wednesday released a report that examines how medical technology is changing the state of health care.

19 Feb 2010

FDA's proposed label changes for LABA asthma medications: GSK reviews

GlaxoSmithKline is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK's Advair (salmeterol / fluticasone propionate). GSK and makers of the other affected medicines containing LABAs have 30 days to agree with the proposed changes or state why they are not warranted.

19 Feb 2010

Asthma: LABAs should not be used alone

The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications.

19 Feb 2010

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

19 Feb 2010

Lower dose of avosentan drug may provide more favorable results in diabetes patients

The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious side effects, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

18 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

OPKO Health acquires Pharmacos Exakta

OPKO Health, Inc. today announced that it has completed the acquisition of Pharmacos Exakta, S.A. de C.V. (“Pharmacos Exakta”), a privately-owned Mexican pharmaceutical company engaged in the manufacture, marketing and distribution of ophthalmic and other pharmaceutical products for government and private markets since 1957. OPKO acquired Pharmacos Exakta, including a manufacturing facility owned by an affiliate, for cash and shares of OPKO Common Stock.

18 Feb 2010

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.

18 Feb 2010

NPG becomes official media partner to the 2010 WIN Symposium

Nature Publishing Group (NPG) is the official media partner to the 2010 WIN (Worldwide Innovative Networking) Symposium, it was announced today. The second annual WIN Symposium, which will be held in the Palais des Congrès, Paris, 7–9 July 2010, will bring together hundreds of oncology researchers from around the world to discuss how best to tailor therapies for patients with cancer.

18 Feb 2010

Patient-centered medical home concept to benefit pharmaceutical industry

HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that the pharmaceutical industry stands to gain from the patient-centered medical home concept that continues to gain traction across the country. According to the recent New England Health Plan Analysis, medical home projects seek to maintain costs and improve health through better treatment compliance, including prescription drug regimens.

18 Feb 2010

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.

18 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Aptuit develops proprietary production screen to understand API and drug formulations

Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.

18 Feb 2010

Study demonstrates once-a-week TB drug is as effective as daily dose

Researchers at the Council for Scientific and Industrial Research (CSIR) are one step closer to providing Tuberculosis (TB) sufferers with a once-a-week medicinal regime rather than their current daily doses.

18 Feb 2010

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

A study by researchers at the University of Cincinnati Neuroscience Institute at University Hospital supports the use of an alternative medication to prevent seizures in patients who have suffered a life-threatening traumatic brain injury or bleeding stroke.

18 Feb 2010

Medication therapy management programs for Aetna Medicare members

Aetna today announced that members who enroll in its 2010 Medicare plans will have access to enhanced services called medication therapy management (MTM) aimed at helping them safely and effectively take medications prescribed by their physician. MTM, which will be delivered by Mirixa Corporation, brings together pharmacists, patients, physicians and other health care professionals to help patients with their medications.

18 Feb 2010

Pharmaceutical News

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Valensa International enters into license agreement with Biova for BiovaFlex ingredient

Report examines how medical technology changes state of health care

FDA's proposed label changes for LABA asthma medications: GSK reviews

Asthma: LABAs should not be used alone

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Lower dose of avosentan drug may provide more favorable results in diabetes patients

FDA approves Rituxan-FC combination therapy for CLL

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Rituxan, intended for patients with CLL receives FDA approval

OPKO Health acquires Pharmacos Exakta

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

NPG becomes official media partner to the 2010 WIN Symposium

Patient-centered medical home concept to benefit pharmaceutical industry

Combination therapy that delays nursing home admission for AD earns 43% patient share in U.S. and 30% in Europe

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Aptuit develops proprietary production screen to understand API and drug formulations

Study demonstrates once-a-week TB drug is as effective as daily dose

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

Medication therapy management programs for Aetna Medicare members

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News